Why My Price Target for Valeant Pharmaceuticals Intl Inc. Is $0

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) should not be bought at any price.

The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) reported unaudited results for the fourth quarter of 2015, and they were ugly to say the least. We’ll take a closer look at the numbers and also look at why the stock shouldn’t be bought at any price.

Very disappointing numbers

If there was any good news, it’s that Valeant generated US$2.8 billion during the fourth quarter. Otherwise, there is nothing positive to report.

Valeant’s Q4 earnings per share (EPS) came in at US$2.50, which was US$0.11 below consensus estimates. But the real bad news came when the company gave its updated guidance. For the year 2016, Valeant expects revenue between US$11 billion and US$11.2 billion, down from prior guidance of US$12.5-12.7 billion. EPS is expected to come in at US$9.50-10.50, again, down from prior guidance, which was US$13.25-13.75.

Even more worryingly, Valeant forecasted US$6.2-6.6 billion in adjusted EBITDA in the 12 months following March 31, but then lowered that estimate to US$6 billion during the earnings call. Management blamed the error on a “typo,” but it’s another sign that they don’t have a handle on their own business.

More trouble from here

Ever since Valeant’s relationship with Philidor was exposed, the company has found itself under increased scrutiny, and that seems to have affected the rest of its business. In the press release, Valeant noted that business slowed in a number of areas, even ones that weren’t a big part of Philidor. For example, Valeant’s gastrointestinal business experienced softer-than-expected sales in the fourth quarter.

This scrutiny will only grow more intense. Politicians are angry about Valeant’s high drug prices. Investigations from the SEC and other public bodies are ongoing. And we still haven’t gotten to the bottom of what was going on at Philidor.

A default could be looming

Valeant’s biggest problem now is its balance sheet. The company has over US$30 billion of debt on its books and has plans to pay down US$1.7 billion this year. But the efforts may not be enough.

If Valeant does not submit its annual report by Thursday, it will breach the covenants on its bonds, paving the way for a default. From there, the company will have a 60-day window to make the proper filings and avoid defaulting.

Here’s the problem though: after the latest numbers came in lower than expected, Valeant may have already breached one of its debt covenants. And that may be why the company has yet to release audited results. To be fair, that is just speculation at this point. But Valeant has also said it intends to enter into negotiations with its creditors regarding covenants.

This is why Valeant’s shares could easily reach $0, and I wouldn’t recommend buying the shares at any price. Put another way, this story is nowhere near over.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned.  Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »